Myfembree® (relugolix/estradiol/norethindrone acetate) – New drug approval
May 26, 2021 - Myovant Sciences and Pfizer announced the FDA approval of Myfembree (relugolix/estradiol/norethindrone acetate), for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Top